Abstract: A medical implant is disclosed. The medical implant includes a body having a first end having a first cross-sectional dimension, a second end having a second cross-sectional dimension, and a tapered portion extending between the first end and the second end. The first cross-sectional dimension is larger than the second cross-sectional dimension. In some embodiments, the body comprises multiple layers.

Abstract: Disclosed herein is a contact lens. Some disclosed embodiments comprise a lenticular aspect. In some instances the lenticular aspect varies in at least one of thickness, distance from the edge of the contact lens, or lenticular height along its length. In one aspect, a superior portion of the lenticular aspect attaches to an upper eyelid of a wearer by at least a portion of the lenticular aspect interacting with an upper tarsal plate of the upper eyelid of a wearer.

Abstract: Methods for applying a sphingolipid aggregate coating to a surface of a substrate for inhibition and prevention of biofilm growth, methods for inhibiting and preventing biofilms, biofilm-inhibiting coatings and coated devices are provided. Coating processes include suspending an amount of sphingolipid in a medium-to-fast-evaporating organic solvent; b) applying energy to the suspension sufficient to create a colloidal dispersion of sphingolipid in the solvent; c) heating the dispersion sufficient to create a solution; and d) coating the surface of the substrate with at least one application of solution, each application followed directly by a complete solvent evaporation period. The resulting coatings exhibit aggregate architectures particularly effective for inhibition and prevention of biofilms.

Abstract: An intraocular drug delivery platform including a ring having an anterior surface and a posterior surface opposite the anterior surface, a central aperture formed by the ring, a first haptic coupled to and extending outwards from the ring, a second haptic coupled to and extending outwards from the ring, a first drug eluting mass operably coupled to the anterior surface of the ring, and a second drug eluting mass operably coupled to the anterior surface of the ring and positioned directly opposite of the first drug eluting mass.

Abstract: A cationic contact lens is described as well as methods of manufacturing the same. The cationic contact lens includes a polymeric lens body that is the reaction product of a polymerizable composition that includes at least one siloxane, at least one nonionic hydrophilic monomer and at least one acyclic tertiary amine monomer. The cationic contact lens can be an unworn sterile silicone hydrogel contact lens. The contact lens is capable of substantially linear release of a releasable anionic agent and the at least one acyclic tertiary amine monomer facilitates uptake and/or sustained release of the releasable anionic agent by the polymeric lens body. The contact lens can be present in a sealed contact lens package.

Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.

Abstract: The present disclosure provides compositions that enable sustained release of a small molecule tyrosine kinase inhibitor, such as axitinib from a bioerodible polyester polymer implant for the treatment of disease. The composition is especially suitable for treating ophthalmic indications, such as neovascular age related macular degeneration and diabetic macular edema, by intravitreal injection of the implant. The implant is designed to be pre-loaded into a small diameter needle and injected via self-sealing scleral needle penetration at the pars plana. Small molecule tyrosine kinase inhibitors may be released from the implants over a period of one week to three years.

Abstract: The disclosed subject matter relates to a cleavable microneedle for delivery of therapeutic agent, wherein the needle includes a longitudinal body having a detachable portion that comprises at least one therapeutic agent. The microneedle may be configured to administer the therapeutic agent to the inner ear of a subject. Also disclosed is a method for preparing a microneedle using two-photon polymerization lithography.

Abstract: Disclosed are high refractive index, hydrophobic, acrylic materials. These materials have both high refractive index and a high Abbe number. This combination means the materials have a low refractive index dispersion and thus are especially suitable for use as intraocular lens materials. The materials are also suitable for use in other implantable ophthalmic devices, such as keratoprostheses, corneal rings, corneal implants, and corneal inlays.

Abstract: The objective of the present invention is to provide a contact lens solution that is safer to eyes such that it has little or no effects on eye tissue and has the versatility that makes the solution applicable to a wide range of contact lenses, while exhibiting desirable anti-Acanthamoeba activity. The objective is achieved by the anti-Acanthamoeba contact lens solution containing a cationic polymer having an average molecular weight in a range of 150,000 to 1,600,000 and having in its molecule a diallyldimethylammonium chloride unit and an inorganic salt.

Abstract: A person's iris color can lighten, such as from brown to lighter brown, green, hazel, or blue, by introducing a melanocyte-killing agent through the cornea of the person's eye and contacting the anterior surface of the iris with the agent at a dose sufficient to kill melanocytes in the iris stroma.

Abstract: The present disclosure is directed to a composite implant for the sustained release of a therapeutic agent from a hydrogel matrix. The hydrogel matrix may be a cross-linked bioerodible polyethylene glycol (PEG) hydrogel with a therapeutic complex dispersed within the cross-linked bioerodible PEG hydrogel. The therapeutic complex may include a therapeutic agent in association with mesoporous silica particles. The composite implant is configured to be delivered to or implanted into an eye of a subject or patient. The composite implant may be used treat ocular disease in a subject or patient. Ocular diseases may be selected from at least one of neovascular age related macular degeneration (AMD), diabetic macular edema, or macular edema following retinal vein occlusion.

Abstract: The invention relates to an artificial eye lens comprising an optical part, which has a first optical side as viewed in a direction of an optical principal axis of the artificial eye lens and an opposite second optical side, wherein a structure with at least one depression is formed in a haptic arrangement of the artificial eye lens and/or in a surround that surrounds the optical part at least in certain areas and that differs from the haptic arrangement, wherein the structure is formed as a micro-perforation with a multiplicity of perforation zones and at least some perforation zones are filled at least in certain areas with at least one medicament for the purposes of producing a medicament repository. The invention also relates to a method for producing such an artificial eye lens.

Abstract: Compositions containing a phenylquinoline derivative compound having peroxisome proliferator-activated receptor a (PPAR?) agonistic activity, and methods of their use in enhancing PPAR? activity in retinal cells, and in treating ocular disorders or conditions, such as but not limited to retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and diabetic macular edema are disclosed.

Abstract: Provided is an orthokerato lens including a central portion located on a center of a lens and configured to change a refractive index by pressurizing a cornea, a fitting portion configured to form a negative pressure between the lens and the cornea to pile epithelial cells moved from the central portion, a fixing portion configured to be in contact with an eyeball and align the lens such that the center of the lens is located at a center of the cornea, a peripheral portion configured to allow tears between the lens and the eyeball to circulate, and a circulation hole configured to penetrate the central portion.

Abstract: Implantable drug delivery devices include a housing having a closed drug reservoir lumen bounded by a first wall structure and a hydrophilic second wall structure, and a drug contained in the drug reservoir lumen, wherein the first wall structure is impermeable to the drug and the second wall structure is permeable to the drug. Methods of providing controlled release of drug to a patient include deploying a drug delivery device in the patient releasing a drug from the drug reservoir lumen via diffusion through the second wall structure.

Abstract: A method for sustained delivery of an agent to an ocular organ in a subject, comprising topically delivering to the ocular surface a liquid thermoresponsive hydrogel comprising agent-loaded polymer microparticles, wherein the agent is sustainably released for a period of at least five days.

Abstract: A minimally invasive controlled drug delivery system for delivering a particular drug or drugs to a particular location of the eye, the system including a porous film template having pores configured and dimensioned to at least partially receive at least one drug therein, and wherein the template is dimensioned to be delivered into or onto the eye.

Abstract: Described herein are compositions composed of micronized placental components and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the micronized compositions are also described herein.

Abstract: Described herein are compositions composed of micronized placental components and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the micronized compositions are also described herein.

Abstract: The present invention relates to the therapeutic use of acylated piceid derivative compounds in ocular pathologies, in particular retinitis pigmentosa and in age-related macular degeneration.

Abstract: The present disclosure provides an ophthalmic article. The ophthalmic article may comprise a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer. The ophthalmic article may also comprise an active agent or a diagnostic agent. The ophthalmic article may be configured to associate to a haptic of an intraocular lens (IOL).

Abstract: Multilayer thin film devices that include a bioactive agent for elution to the surrounding tissue upon administration to a subject are provided. The multilayer thin film devices are useful as medical devices, such as ocular devices. Also provided are methods and kits for localized delivery of a bioactive agent to a tissue of a subject, and methods of preparing the subject devices. The multilayer thin film medical device includes a first layer, a bioactive agent and a second layer. The first and the second layers may be porous or non-porous. The devices have a furled structure, suitable for administration to a subject.

Abstract: Devices, methods and kits are described for reducing intraocular pressure. The devices include a support that is implantable within Schlemm's canal and that may restore or maintain at least partial patency of the canal without substantially interfering with transmural or transluminal fluid flow across the canal. The devices utilize the natural drainage process of the eye and may be implanted with minimal trauma to the eye. Kits may include a support and an introducer for implanting the support within Schlemm's canal. Methods may include implanting a support within Schlemm's canal, where the support is capable of restoring or maintaining at least partial patency of the canal without substantial interference with transmural or transluminal fluid flow across the canal.

Abstract: Disclosed herein are substrates for cell delivery to target tissues requiring treatment for various diseases that induce cell death, damage or loss of function. The substrates are configured to provide seeded cells, including stem cells, with a structural support that allows interconnection with and transmission of biological signals between the cells and the target tissue.

Abstract: This disclosure relates to a drug delivery system comprising an intraocular pressure lowering agent, a neurotrophic agent, such as a CNTF compound, a C-type Natriuretic Peptide (CNP) compound, a Tie-2 agonist, a Natriuretic Peptide Receptor-B (NPR-B) compound, or an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, including any combination of these compounds and a sustained delivery component. Methods of treating a glaucoma or related conditions, medicaments, kits, uses and methods of manufacturing are also described.

Abstract: The invention relates to a composition, in particular a pharmaceutical composition, which is suitable in particular for the prophylactic and/or therapeutic treatment preferably of inflammatory diseases of the urogenital tract, in particular inflammatory diseases of the bladder, preferably cystitis, to the uses thereof, to a storage or application device relating to same, to a packaging unit, and finally to a kit which is designed in particular as an instillation system.

Abstract: An implant to fill a hole in tissue, such as bone tissue, comprising a first portion that is insertable through the hole when in a first compressed position, wherein the first portion cannot pass through the hole when in a first deployed position; and a second portion that cannot pass through the hole when in the second deployed position. The first and second portions of the implant can be deployed independently. Therefore, in operation, it is possible to insert the first portion of the implant through the hole when in the first compressed position, deploying the first portion to transition it to the first deployed position while the second portion remains in the second compressed position, and then deploying the second portion to transition it to the second deployed position. The devices and methods may be used, for example, in transsphenoidal or other orthopedic surgeries involving bone tissue.

Abstract: Use of activated protein C (APC) for treatment and prevention of ocular diseases, disorders or conditions associated with retinal leakage and CNV such as age-related macular degeneration, optionally in combined therapy with anti-angiogenesis, anti-inflammatory, immunosuppressive, and anti PDGF agent.

Abstract: Methods for treatment of dry eye and other acute or chronic inflammatory processes are disclosed herein. One method includes administering a drug delivery implant to a patient in need thereof, the drug delivery implant comprising one or more Rock inhibitors and/or one or more Wnt inhibitors, the patient having a medical condition selected from the group consisting of dry eye, lichen planus, arthritis, psoriasis, plantar fasciitis, pars planitis, scleritis, keratitis, chronic meibomian gland inflammation, optic nerve neuritis, uveitis, papillitis, diabetic neural pain, diabetic retinopathy, a cataract, a side effect occurring after refractive surgery, a side effect occurring after corneal transplant, a side effect occurring after retinal detachment surgery, and combinations thereof. The administration of the drug delivery implant to the patient treats the medical condition, reduces the symptoms associated with the medical condition, enhances nerve regeneration, and/or alleviates the medical condition.

Abstract: The present invention provides a sustained drug delivery system for the treatment of age-related macular degeneration (AMD), comprising corticosteroid encapsulated nanoparticles incorporated into a thermoreversible hydrogel. The corticosteroid may be triamcinolone acetate (TA), dexamethasone, or loteprednol etabonate (LE). The proposed drug delivery system is nontoxic to ARPE-19 (retinal pigment epithelium) cells and significantly reduces VEGF (vascular endothelial growth factor) expression as compared to solutions of the coticosteroids. The present invention provides sustained delivery of the corticosteroid to the posterior segment of the eye, reducing the frequency of intraocular injections necessary to maintain therapeutic concentrations.

Abstract: The present invention pertains to a composition comprising at least one biocompatible and biodegradable polymer, the polymer further comprising nanocarriers wherein the nanocarriers comprise a drug. Moreover, also encompassed by the invention is the use of the composition in the treatment of a disease and a method for manufacturing the composition.

Abstract: Cross-linking agent(s), composition(s) made therefrom and use(s) thereof. For example, crosslinking agent(s) that are used to make composition(s) such as hydrogel material(s). Such materials are useful in the manufacture of biocompatible medical devices, for example, hydrogel materials having desirable physical properties for use as contact lense(s) and/or stimulating device(s).

Abstract: A wearable liquid supplying device for insulin injection is fixed on a user's body through a ring belt and includes a carrier body, a flow-guiding-and-actuating unit, a sensor, an air bag, a miniature air pump and a driving chip. The sensor measures sweat on human skin to detect a level of the blood glucose. The driving chip receives the glucose monitoring data and accordingly controls the actuation of the flow-guiding-and-actuating unit and the open/closed states of the switching valves. The miniature air pump is enabled to inhale gas into the air bag, so that the air bag is inflated and the ring belt contacts the human skin tightly. The flow-guiding-and-actuating unit is enabled to generate a pressure difference so that the insulin liquid is transported to a liquid guiding outlet through a liquid guiding channel and flows into the microneedle patch for being injected into the subcutaneous tissue.

Abstract: A wearable liquid supplying device for human insulin injection is fixed on a body of human through a ring belt and includes a substrate, a flow-guiding-and-actuating unit, a sensor and a driving chip. The substrate has a liquid storage chamber. The flow-guiding-and-actuating unit has a liquid guiding channel in communication with a liquid storage outlet of the liquid storage chamber and a liquid guiding outlet. The sensor measures a blood glucose level and generates measured data correspondingly. The driving chip receives the measured data from the sensor and controls the actuation of the flow-guiding-and-actuating unit and the open/closed states of the switching valves. The flow-guiding-and-actuating unit is enabled to generate a pressure difference so that the insulin liquid is transported to the liquid guiding outlet through the liquid guiding channel and flows into the microneedle patch for allowing the microneedles to inject the insulin liquid into the subcutaneous tissue.

Abstract: Drug delivery devices comprising a non-bioabsorbable polymer structure configured to support a composition comprising an active agent. The devices include a plurality of portions fused together and a recess configured to support the composition. At least one of the portions includes an impermeable polymer and at least one other portion includes a rate-limiting water-permeable polymer. The rate-limiting water-permeable polymer allows for transportation of the active agent to an exterior of the device.

Abstract: Multilayer thin film devices that include a bioactive agent for elution to the surrounding tissue upon administration to a subject are provided. The multilayer thin film devices are useful as medical devices, such as ocular devices. Also provided are methods and kits for localized delivery of a bioactive agent to a tissue of a subject, and methods of preparing the subject devices. The multilayer thin film medical device includes a first layer, a bioactive agent and a second layer. The first and the second layers may be porous or non-porous. The devices have a furled structure, suitable for administration to a subject.

Abstract: Methods of using botulinum toxin based pharmaceuticals are disclosed. The methods cause vasodilatation and decreased flow resistance of certain vascular beds for the purpose of increasing blood flow to a region in order to positively impact deterioration from a number of diseases.

Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Abstract: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.

Abstract: An aqueous suspension preparation that comprises a macrolide antibacterial agent as an active component. The aqueous suspension preparation is characterized by comprising nanoparticles of a macrolide antibacterial agent and a dispersion stabilizer; an aqueous suspension in which the average particle size of nanoparticles is 500 nm or less and the D90 particle size is 1,500 nm or less; a parenterally administered pharmaceutical composition that comprises this aqueous suspension preparation; an injection preparation; and eye drops or ear drops, more specifically, eye drops for the treatment or prevention of inflammatory diseases of the eye or ear drops for the treatment or prevention of inflammatory diseases of the ear.

Abstract: A therapeutic delivery device that provides a controlled release of high doses of a therapeutic agent in a local area, sustains the high dose controlled release with a percutaneous port for refilling the device, and is versatile for use with multiple types of therapeutic agents and/or implant systems. A rate determining/controlled release membrane is used to decrease the molecular mobility of the therapeutic compounds thereby controlling the therapeutic release profile. The therapeutic delivery device includes a body defining an internal reservoir for receiving a therapeutic agent and including a first membrane for providing a controlled release of the therapeutic agent to the surgical site, a port in fluid communication with the reservoir, a sleeve configured to encapsulate the body, and a rigid housing configured to support the body and a portion of the sleeve, the rigid housing configured to release the body and the sleeve after the body and the sleeve are anchored position relative to the surgical site.

Abstract: A liquid supplying device for a human insulin injection includes a substrate, a liquid storage chamber, a flow-guiding-and-actuating unit, a sensor and a driving chip. The flow-guiding-and-actuating unit includes a liquid guiding channel having a liquid guiding outlet in fluid communication with a liquid storage outlet of the liquid storage chamber. The sensor contacts with the human skin to measure a blood glucose level contained in sweat. The driving chip is configured to control the actuation of the flow-guiding-and-actuating unit, control open/closed states of the switching valves and receive the measured data from the sensor for determination. By driving the flow-guiding-and-actuating unit, a pressure gradient is generated, and an insulin liquid stored in the liquid storage chamber is transported to the liquid guiding outlet through the liquid guiding channel, flowing into a microneedle patch, and injected into a subcutaneous tissue through a plurality of hollow microneedles.

Abstract: Disclosed are high refractive index, hydrophobic, acrylic materials. These materials have both high refractive index and a high Abbe number. This combination means the materials have a low refractive index dispersion and thus are especially suitable for use as intraocular lens materials. The materials are also suitable for use in other implantable ophthalmic devices, such as keratoprostheses, corneal rings, corneal implants, and corneal inlays.

Abstract: The present invention relates to a preservative-free, aqueous solution in the form of eye drops packed in a container that ensures stability of the product, ideal eye drop volume and reduced drop volume variability and provides efficient dispensing.

Abstract: A conformable covering comprises an outer portion with rigidity to resist movement on the cornea and an inner portion to contact the cornea and provide an environment for epithelial regeneration. The inner portion of the covering can be configured in many ways so as to conform at least partially to an ablated stromal surface so as to correct vision. The conformable inner portion may have at least some rigidity so as to smooth the epithelium such that the epithelium regenerates rapidly and is guided with the covering so as to form a smooth layer for vision. The inner portion may comprise an amount of rigidity within a range from about 1×10?4 Pa*m3 to about 5×10?4 Pa*m3 so as to deflect and conform at least partially to the ablated cornea and smooth an inner portion of the ablation with an amount of pressure when deflected.

Abstract: The invention relates to devices and methods for deploying an implant. Preferably the device (10) deploys a flexible implant in an eye. In one embodiment, the device comprises a distal end and a proximal end, wherein the distal end is constructed and arranged to cause said implant to be flexed into a curved configuration when in a carried position and the device is configured to urge said flexed implant from said carried position to a deployed position. Embodiments with removable tips (13) and wheel actuators (14) are also disclosed.

Abstract: A microneedle including a projection having a through hole formed in the projection in a direction that the projection extends, and a tubular member having an end surface configured to support the projection when the end surface is pressed against a skin and a fluid is supplied through the through hole of the projection to the skin. The projection has a length H along the direction that the projection extends and the supporting surface has an area S such that a ratio of S/H is in a range of from 2.1 to 10.5.

Abstract: A surgical tool for inserting a spile or plug into the punctal opening of a meatus such as a lacrimo-nasal canaliculus. The tool includes a distal end having a plug-carrying structure which includes distally extending rod for engaging an axial bore in the plug, and an abutment having a radial prominence supporting a penetration-resisting bearing surface which prevents over-insertion of the plug by contacting tissue surrounding the punctal opening. The abutment can be shaped and dimensioned to provide effective and comfortable penetration resistance while affording ample visibility to the surgeon user. The rod can be axially withdrawn through a rod tracking tube having a precisely dimensioned central lumen restricting off-axis movement of the rod. The abutment can be fixed to the rod or detached from it.

Abstract: The present invention provides an optical element which prevents a contaminant component adhering to the edge thereof from spreading through the capillary action and thus from forming a stain; and a display device including the element. The present invention directs to an optical element including: a base material including a front surface provided with projected portions at a pitch equal to or shorter than the wavelength of visible light, and a side surface surrounding the front surface; and a covering material covering at least one of an edge of the front surface and the side surface, the covering material filling gaps between the projected portions. The present invention also directs to a display device including such an optical element.